Hyaluronic acid eye drops, start to revise the standard

for reducing usage

The HIRA is scheduled to hold an expert advisory meeting

The HIRA has started to revise the standards to limit the use of Hyaluronic acid sodium eye drops.

 

It is known that the revision of standards will be completed as early as the end of the year, and will be implemented from next year.

 

According to an industry example on the 10th, the HIRA has entered a review of the revision of the standards for sodium hyaluronic acid eye drops at the request of the Ministry of Health and Welfare.

 

Therefore, we plan to hold an expert advisory meeting soon to continue related discussions.

 

Earlier, the Pharmaceutical Benefit Evaluation Committee held on the 6th of last month recognized the benefit of endogenic diseases for Hyaluronic acid eye drops that have been reassessed.

 

Exogyneutic disease is caused by post-surgery, pharmaceutical, trauma, wearing of content lenses, etc.

 

Endogenic diseases include Sjogren's syndrome, skin blemish syndrome (Steven's Johnson syndrome), and dry eye syndrome.

 

The main indication of hyaluronic acid eye drops is an endogenic disease, so related companies sighed with relief.

 

However, instead of recognizing the benefit of endogenic diseases, the drug review committee put a clue that it is necessary to set the prescribed amount per patient's visit and the total annual prescription amount per patient in the standard for proper use.

 

As a result, it is more likely to affect sales due to the revision of standards.

 

During the discussion of the re-evaluation, it was known that a plan to limit 1 bottle of 60 to 4 per year was also considered.

 

It is said that the HIRA reported the results of the drug level to the Ministry of Health and Welfare, and the Ministry of Health and Welfare requested a revision of the salary standard.

 

Therefore, it is expected to speed up the revision of salary standards through expert advisory meetings, etc.

 

Since the results of this year's benefit decent revaluation will be reflected from January next year, it is known that the discussion on the revision of the salary standard of the Hyaluronic acid drop system will be completed within this year and implemented at the same time as the results of the reassessment in January next year.

 

An official from a related company explained, "If you limit the amount of use, even if the benefit is recognized for endogenic diseases, damage to sales is inevitable." The three-year average claim amount of hyaluronic acid eye drops is 231.5 billion won, and about 400 items are listed as reimbursement.